2 Pharma Stocks that Zoomed Due to COVID Drugs
By Aditya Raghunath Investing.com -- The second wave of the coronavirus keeps mutating and its side effects are as bad as the disease itself. While the number of infections has been steadily...
Neutral
or
Natco Pharma News & Analysis
-
-
Natco Pharma share price hits 20% upper circuit, stock at new record high on starting trials for COVID drug
Natco Pharma share price hits 20 per cent upper circuit at Rs 1,188.95 apiece, also its all-time high, in intraday on BSE, after the company initiated phase III clinical trial to evaluate...
-
Natco Pharma hits record highs on drug approvals
The stock opened at a 52-week high of ₹1,188.95
-
Why Natco Pharma share zoomed 20% today
Presently six firms - BDR Pharma, Bharat Serums and Vaccines, Mylan, Sun Pharma, Cipla, and Life Care - are producing Amphotericin B
-
Natco Pharma Hit 52-Week High On Approval of Black Fungus Drug
On May 24, the share price of Natco Pharma increased by more than 20% after the Drug Controller General of India (DCGI) authorized five firms, including Natco Pharma. The approval is to...
-
JTEKT India Ltd leads gainers in 'A' group
Astec Lifesciences Ltd, Birlasoft Ltd, Dollar Industries Ltd and Natco Pharma Ltd are among the other gainers in the BSE's 'A' group today, 24 May 2021.
-
Natco Pharma shares hit upper circuit. Here's why
The Hyderabad-based firm said the first dose under the phase-III trials was given to a patient in the city-based Yashoda Hospitals.
-
Natco Pharma surges 20%, hits new high on USFDA nod for cancer drug
The company has received approval from the US health regulator for the generic version of Celgene's multiple myeloma drug, Revlimid (Lenalidomide) capsules in the US
-
Natco Pharma share price hits 52- week high on DCGI nod for production of #39;Black Fungus#39; drug
DCGI approved application of five companies incuding Natco Pharma to begin production of antifungal drug Amphotericin B liposomal injection, which is critical in the treatment of...
-
-
Stocks in the news: Grasim, SBI, JSW Steel, Dr Reddy's Labs, India Cements and Natco Pharma
The country's largest lender reported an 80.15 per cent jump in its standalone profit after tax (PAT) of Rs 6,451 crore in the three months to March 2021.
-
Natco Pharma gets American drug regulator's nod for generic cancer treatment drug
Natco, along with its marketing partner Arrow International previously settled the Paragraph IV litigation related to the product with Celgene, now part of Bristol-Myers Squibb, who sells...
-
Natco Pharma gets USFDA nod for lenalidomide capsules
The drug maker has received final approval for lenalidomide capsules of 5mg, 10mg, 15mg, and 25mg strengths from the US Food and Drug Administration (USFDA).
-
Natco Pharma receives USFDA approval for Everolimus Tablets
NATCO's partner BPI plans to launch 0.25 mg, 0.5 mg and 0.75 mg strengths of the product shortly.
-
Natco Pharma receives USFDA approval for Lenalidomide Capsules
NATCO, along with its marketing partner Arrow International (a U.S. affiliate of Teva Pharmaceutical Industries Ltd), previously settled the Paragraph IV litigation related to the product...
-
Natco Pharma initiates Phase III clinical trial of Molnupiravir capsules
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved...
-
Natco Pharma ties with Eli Lilly for manufacturing Baricitinib to treat Covid; Stock gains 1%
NATCO had received an emergency use authorization for Baricitinib tablets, from Central Drugs Standard Control Organization (COSCO).
-
Natco Pharma signs licensing agreement with Eli Lilly
For manufacture and commercialization of Covid-19 drug - Baricitinib
-
Natco Pharma signs pact with Eli Lilly for COVID drug in India
The drug maker signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for COVID-19...
-
Eli Lilly inks pact with Natco Pharma for Covid-19 drug baricitinib
Drug firm Eli Lilly said it has signed a voluntary licensing agreement with Natco Pharma to further expedite the availability of baricitinib for Covid-19 patients in India
-
Eli Lilly buckles under pressure, offers voluntary licence to Natco Pharma
Lily has issued voluntary licenses for Barcitinib to six Indian drug makers besides Natco, these include- Sun Pharma, Cipla, Dr Reddy's, Lupin, Torrent Pharma and MSN Labs. Barcitinib, in...
-
COVID-19 drug Baricitinib: Eli Lilly signs voluntary licensing agreement with Natco Pharma
Natco has received approval from the Drug Controller General of India (DCGI) for Baricitinib earlier in May. Natco went ahead and launched the drug under brand name Barinat even as its...
-
UPDATE 1-India approves Roche/Regeneron antibody cocktail to treat COVID-19
(Adds details on the drug, background)BENGALURU, May 5 (Reuters) - India has given emergency use authorization for a COVID-19 antibody drug cocktail developed by Roche ROG.S and Regeneron...
-
How Natco Pharma put US drug giant Eli Lilly under pressure for COVID-19 drug through compulsory licensing filing
The Indian company says it has offered 7% royalty to the US drugmaker for Baricitinib. Natco has filed for compulsory licensing, arguing that Eli Lillyâs small distribution network wonât...
-
Natco Pharma share climbs 4% on emergency nod for Covid-19 medicine
The company is ready to launch the product this week, so as to make the product available to suffering patients across India
-
BRIEF-Natco Pharma Gets Emergency Use Nod For Baricitinib Tablets For COVID-19 Treatment
May 3 (Reuters) - Natco Pharma Ltd NATP.NS :* NATCO RECEIVES EMERGENCY USE APPROVAL FOR BARICITINIB TABLETS FOR COVID-19 TREATMENT* NATCO WILL BE REQUESTING A COMPULSORY LICENSE BASED ON...
-
Coronavirus treatment: 5 Indian firms in licensing pact with Merck for Covid-19 oral drug
Molnupiravir is an investigational oral antiviral agent, currently being studied in a Phase 3 trial for the treatment of non-hospitalised patients with confirmed COVID-19.Meanwhile, Natco...
-
Natco Pharma share climbs 7% as firm seeks nod for COVID-19 drug
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication, according to a press release from Natco
-
Natco Pharma seeks approval for phase-3 trial of antiviral drug Molnupiravir for COVID-19 treatment
As per a press release from the Hyderabad-based company, pre-clinical data has proven that Molnupiravir has broad anti-influenza activity, comprising highly potent inhibition of SARS-CoV-2...
-
Natco Pharma rallies 7% as firm seeks nod for Covid medicine Molnupiravir
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of Covid-19 replication
-
Natco Pharma seeks approval for COVID drug candidate Molnupiravir; shares jump 7%
Natco said it is hoping that CDSCO would give emergency approval of this drug based on âcompassionate useâ for patients.
-
Covid: Natco Pharma seeks approval for Molnupiravir capsules phase 3 trials
Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules
-
Natco Pharma seeks approval for Molnupiravir capsules for use in COVID-19 treatment
According to a press release from the city-based drug maker, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of...
-
Natco Pharma jumps on seeking approval for Molnupiravir
Natco Pharma rose 3.78% to Rs 911 after the company said that it is seeking an emergency approval of Molnupiravir capsules for Covid-19 treatment.
-
COVID-19 treatment | Natco Pharma seeks approval to launch phase-3 trial of Molnupiravir
Natco said it is hoping that CDSCO would give emergency approval of this drug based on âcompassionate useâ for patients.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
